ES2175137T3
(es)
*
|
1995-12-08 |
2002-11-16 |
Janssen Pharmaceutica Nv |
Derivados de (imidazol-5-il)metil-2-quinolinona como inhibidores de laproteina farnesil-transferasa.
|
DE69807222T2
(de)
|
1997-06-02 |
2003-04-17 |
Janssen Pharmaceutica Nv |
(imidazol-5-yl)methyl-2-quinolinone derivativen als inhibitoren von proliferation der glatten muskelzellen
|
US20030114503A1
(en)
*
|
1997-06-16 |
2003-06-19 |
Pfizer Inc. |
Farnesyl transferase inhibitors in combination with HMG CoA reductase inhibitors for the treatment of cancer
|
DK1097150T3
(da)
*
|
1998-06-16 |
2004-07-26 |
Sod Conseils Rech Applic |
Imidazolylderivater
|
US6420555B1
(en)
|
1998-06-16 |
2002-07-16 |
Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. |
Imidazolyl derivatives
|
TR200003882T2
(tr)
*
|
1998-07-06 |
2001-06-21 |
Janssen Pharmaceutica N.V. |
Artropatilerin tedavisi için farnesil protein transferaz inhibitörleri.
|
EA003877B1
(ru)
*
|
1998-07-06 |
2003-10-30 |
Янссен Фармацевтика Н.В. |
Ингибиторы фарнезилпротеинтрансферазы, обладающие in vivo радиосенсибилизирующими свойствами
|
FR2780892B1
(fr)
*
|
1998-07-08 |
2001-08-17 |
Sod Conseils Rech Applic |
Utilisation d'inhibiteurs de prenyltransferases pour preparer un medicament destine a traiter les pathologies qui resultent de la fixation membranaire de la proteine g heterotrimerique
|
OA11645A
(en)
*
|
1998-08-27 |
2004-11-16 |
Pfizer Prod Inc |
Alkynyl-substituted quinolin-2-one derivatives useful as anticancer agents.
|
CA2341739C
(en)
|
1998-08-27 |
2005-07-12 |
Pfizer Products Inc. |
Quinolin-2-one derivatives useful as anticancer agents
|
AU2478500A
(en)
|
1998-12-08 |
2000-06-26 |
Merck & Co., Inc. |
Inhibitors of prenyl-protein transferase
|
WO2000034437A2
(en)
|
1998-12-08 |
2000-06-15 |
Merck & Co., Inc. |
Inhibitors of prenyl-protein transferase
|
EE04962B1
(et)
*
|
1998-12-23 |
2008-02-15 |
Janssen Pharmaceutica N.V. |
Kinoliini ühend, seda sisaldav farmatseutiline kompositsioon, ühendi kasutamine ravimina ning meetod ühendi ja kompositsiooni valmistamiseks
|
UA71945C2
(en)
|
1999-01-27 |
2005-01-17 |
Pfizer Prod Inc |
Substituted bicyclic derivatives being used as anticancer agents
|
JP3270834B2
(ja)
|
1999-01-27 |
2002-04-02 |
ファイザー・プロダクツ・インク |
抗がん剤として有用なヘテロ芳香族二環式誘導体
|
DE60020812T2
(de)
|
1999-02-11 |
2006-05-04 |
Pfizer Products Inc., Groton |
Heteroaryl-substituierte chinolin-2-on derivate verwendbar als antikrebsmittel
|
US6143766A
(en)
*
|
1999-04-16 |
2000-11-07 |
Warner-Lambert Company |
Benzopyranone and quinolone inhibitors of ras farnesyl transferase
|
EP1420015A1
(en)
*
|
1999-06-11 |
2004-05-19 |
Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. |
Imidazolyl derivatives
|
FR2796943A1
(fr)
*
|
1999-07-30 |
2001-02-02 |
Aventis Pharma Sa |
Derives de benzoxazinnes, leur procede de preparation et leur utilisation en therapeutique
|
RU2298417C2
(ru)
*
|
1999-11-09 |
2007-05-10 |
Сосьете Де Консей Де Решерш Э Д`Аппликасьон Сьентифик (С.К.Р.А.С.) |
Продукт, включающий ингибитор трансдукции сигналов гетеротримерных протеинов g в комбинации с другим цитостатическим средством, для терапевтического применения при лечении рака
|
ATE259365T1
(de)
*
|
1999-11-30 |
2004-02-15 |
Pfizer Prod Inc |
Chinolinderivate verwendbar zur hemmung der farnesyl-protein transferase
|
HN2000000266A
(es)
*
|
2000-01-21 |
2001-05-21 |
Pfizer Prod Inc |
Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto.
|
SI1255537T1
(sl)
*
|
2000-02-04 |
2006-10-31 |
Janssen Pharmaceutica Nv |
Inhibitorji farnezil protein transferaze za zdravljenje raka dojk
|
US6838467B2
(en)
|
2000-02-24 |
2005-01-04 |
Janssen Pharmaceutica N. V. |
Dosing regimen
|
JP2003525246A
(ja)
*
|
2000-02-29 |
2003-08-26 |
ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ |
白金化合物とのファルネシルタンパク質トランスフェラーゼ阻害剤の組み合わせ剤
|
CA2397446A1
(en)
*
|
2000-02-29 |
2001-09-07 |
Janssen Pharmaceutica Inc. |
Combinations of a farnesyl protein transferase inhibitor with nitrogen mustard or nitrosourea alkylating agents
|
JP2003525236A
(ja)
*
|
2000-02-29 |
2003-08-26 |
ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ |
ビンカアルカロイドとのファルネシルタンパク質トランスフェラーゼ阻害剤の組み合わせ剤
|
US20030212008A1
(en)
*
|
2000-02-29 |
2003-11-13 |
Palmer Peter Albert |
Farnesyl protein transferase inhibitor combinations with further anti-cancer agents
|
JP2003525252A
(ja)
*
|
2000-02-29 |
2003-08-26 |
ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ |
Her2抗体とのファルネシルタンパク質トランスフェラーゼ阻害剤組み合わせ剤
|
AU2001239275A1
(en)
*
|
2000-02-29 |
2001-09-12 |
Janssen Pharmaceutica N.V. |
Farnesyl protein transferase inhibitor combinations with anti-tumor podophyllotoxin derivatives
|
WO2001064199A2
(en)
*
|
2000-02-29 |
2001-09-07 |
Janssen Pharmaceutica N.V. |
Farnesyl protein transferase inhibitor combinations with taxane compounds
|
WO2001064197A2
(en)
*
|
2000-02-29 |
2001-09-07 |
Janssen Pharmaceutica N.V. |
Farnesyl protein transferase inhibitor combinations with anti-tumor anthracycline derivatives
|
CA2397240A1
(en)
*
|
2000-02-29 |
2001-09-07 |
Peter Albert Palmer |
Farnesyl protein transferase inhibitor combinations with camptothecin compounds
|
AU2001256166A1
(en)
*
|
2000-02-29 |
2001-09-12 |
Janssen Pharmaceutica N.V. |
Farnesyl protein transferase inhibitor combinations with anti-tumor nucleoside derivatives
|
AU2001252147A1
(en)
*
|
2000-02-29 |
2001-09-12 |
Janssen Pharmaceutica N.V. |
Farnesyl protein transferase inhibitor combinations
|
US6844357B2
(en)
*
|
2000-05-01 |
2005-01-18 |
Pfizer Inc. |
Substituted quinolin-2-one derivatives useful as antiproliferative agents
|
JO2361B1
(en)
|
2000-06-22 |
2006-12-12 |
جانسين فارماسيوتيكا ان. في |
Enaniumer 1,2-anylated quinoline inhibitor for the transporter - farnesyl
|
AU2001293835A1
(en)
|
2000-09-25 |
2002-04-02 |
Janssen Pharmaceutica N.V. |
Farnesyl transferase inhibiting 6-heterocyclylmethyl quinolinone derivatives
|
AU2001293826A1
(en)
|
2000-09-25 |
2002-04-02 |
Janssen Pharmaceutica N.V. |
Farnesyl transferase inhibiting quinoline and quinazoline derivatives as farnesyl transferase inhibitors
|
AU2001293829A1
(en)
*
|
2000-09-25 |
2002-04-02 |
Janssen Pharmaceutica N.V. |
Farnesyl transferase inhibiting 6-((substituted phenyl)methyl)-quinoline and quinazoline derivatives
|
JP4974438B2
(ja)
|
2000-09-25 |
2012-07-11 |
ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ |
ファルネシルトランスフェラーゼを阻害する6−ヘテロシクリルメチルキノリンおよびキナゾリン誘導体
|
ATE434615T1
(de)
|
2000-11-21 |
2009-07-15 |
Janssen Pharmaceutica Nv |
Farnesyltransferase hemmende benzoheterocyclische derivate
|
US20040044032A1
(en)
*
|
2000-11-28 |
2004-03-04 |
End David William |
Farnesyl protein transfer inhibitors for the treatment of inflammatory bowel disease
|
JP2004516287A
(ja)
*
|
2000-12-19 |
2004-06-03 |
ファイザー・プロダクツ・インク |
6−[(4−クロロ−フェニル)−ヒドロキシ−(3−メチル−3h−イミダゾール−4−イル)−メチル]−4−(3−エチニル−フェニル)−1−メチル−1h−キノリン−2−オン,2,3−ジヒドロキシブタン二酸塩の結晶形および製造方法
|
ES2263684T3
(es)
*
|
2000-12-27 |
2006-12-16 |
Janssen Pharmaceutica N.V. |
Derivados de 4-heterociclil-quinolina y -quinazolina que inhiben la farnesil transferasa.
|
DE60117847T2
(de)
*
|
2000-12-27 |
2006-11-16 |
Janssen Pharmaceutica N.V. |
Farnesyltransferase hemmende, in der 4-stellung substituierte chinolin- und chinazolinderivate
|
WO2002056884A2
(en)
*
|
2001-01-22 |
2002-07-25 |
Schering Corporation |
Treatment of malaria with farnesyl protein transferase inhibitors
|
DE60230017D1
(de)
*
|
2001-02-15 |
2009-01-08 |
Janssen Pharmaceutica Nv |
Farnesyl-protein-transferase hemmer in kombination mit antiöstrogenen
|
DE60202755T2
(de)
*
|
2001-03-12 |
2006-03-30 |
Janssen Pharmaceutica N.V. |
Verfahren zur herstellung von imidazolverbindungen
|
US20020151563A1
(en)
*
|
2001-03-29 |
2002-10-17 |
Pfizer Inc. |
Farnesyl transferase inhibitors in combination with HMG CoA reductase inhibitors for the inhibition of abnormal cell growth
|
US6706699B2
(en)
*
|
2001-06-21 |
2004-03-16 |
Ariad Pharmaceuticals, Inc. |
Quinolines and uses thereof
|
WO2003000266A1
(en)
*
|
2001-06-21 |
2003-01-03 |
Ariad Pharmaceuticals, Inc. |
Novel quinolines and uses thereof
|
US6740757B2
(en)
|
2001-08-29 |
2004-05-25 |
Pfizer Inc |
Enantiomers of 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3h-imidazol-4-yl)-methyl]-4-[3-(3-hydroxy-3-methyl-but-1-ynyl)-phenyl]-1-methyl-1h-quinolin-2-one and salts thereof, useful in the treatment of cancer
|
US20030134846A1
(en)
*
|
2001-10-09 |
2003-07-17 |
Schering Corporation |
Treatment of trypanosoma brucei with farnesyl protein transferase inhibitors
|
US7408063B2
(en)
|
2001-12-19 |
2008-08-05 |
Janssen Pharmaceutica, N.V. |
1,8-annelated quinoline derivatives substituted with carbon-linked triazoles as farnesyl transferase inhibitors
|
CA2478813C
(en)
*
|
2002-03-22 |
2011-10-18 |
Janssen Pharmaceutica N.V. |
Benzylimidazolyl substituted 2-quinoline and quinazoline derivatives for use as farnesyl transferase inhibitors
|
AU2003229688B2
(en)
|
2002-04-15 |
2009-07-30 |
Janssen Pharmaceutica N.V. |
Farnesyl transferase inhibiting tricyclic quinazoline derivatives substituted with carbon-linked imidazoles or triazoles
|
US7132100B2
(en)
|
2002-06-14 |
2006-11-07 |
Medimmune, Inc. |
Stabilized liquid anti-RSV antibody formulations
|
US7425618B2
(en)
|
2002-06-14 |
2008-09-16 |
Medimmune, Inc. |
Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
|
US20030125268A1
(en)
*
|
2002-08-28 |
2003-07-03 |
Rybak Mary Ellen Margaret |
Farnesyl protein transferase inhibitor combinations with anti-tumor anthracycline derivatives
|
US20040265315A1
(en)
*
|
2002-09-05 |
2004-12-30 |
Christine Dingivan |
Methods of preventing or treating T cell malignancies by administering CD2 antagonists
|
US7563810B2
(en)
|
2002-11-06 |
2009-07-21 |
Celgene Corporation |
Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
|
US8034831B2
(en)
*
|
2002-11-06 |
2011-10-11 |
Celgene Corporation |
Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
|
KR20120035234A
(ko)
|
2003-04-11 |
2012-04-13 |
메디뮨 엘엘씨 |
재조합 il?9 항체 및 그의 용도
|
US20050003422A1
(en)
|
2003-07-01 |
2005-01-06 |
Mitch Reponi |
Methods for assessing and treating cancer
|
EP1660087A2
(en)
*
|
2003-07-22 |
2006-05-31 |
Janssen Pharmaceutica N.V. |
Quinolinone derivatives as inhibitors of c-fms kinase
|
CA2536238C
(en)
|
2003-08-18 |
2015-04-07 |
Medimmune, Inc. |
Humanization of antibodies
|
US20060228350A1
(en)
*
|
2003-08-18 |
2006-10-12 |
Medimmune, Inc. |
Framework-shuffling of antibodies
|
JP4794445B2
(ja)
*
|
2003-09-23 |
2011-10-19 |
メルク・シャープ・エンド・ドーム・コーポレイション |
キノリンカリウムチャネル阻害剤
|
WO2005089515A2
(en)
*
|
2004-03-18 |
2005-09-29 |
The Brigham And Women's Hospital, Inc. |
Methods for the treatment of synucleinopathies
|
US20050272068A1
(en)
*
|
2004-03-18 |
2005-12-08 |
The Brigham And Women's Hospital, Inc. |
UCH-L1 expression and cancer therapy
|
US20070293539A1
(en)
*
|
2004-03-18 |
2007-12-20 |
Lansbury Peter T |
Methods for the treatment of synucleinopathies
|
EP1732549A4
(en)
*
|
2004-03-18 |
2009-11-11 |
Brigham & Womens Hospital |
METHOD FOR THE TREATMENT OF SYNUCLEINOPATHIES
|
WO2005089502A2
(en)
*
|
2004-03-18 |
2005-09-29 |
The Brigham And Women's Hospital, Inc. |
Methods for the treatment of synucleinopathies
|
WO2005089504A2
(en)
*
|
2004-03-18 |
2005-09-29 |
The Brigham And Women's Hospital, Inc. |
Methods for the treatment of synucleinopathies
|
US7572916B2
(en)
|
2004-05-03 |
2009-08-11 |
Janssen Pharmaceutica Nv |
Diastereoselective synthesis process with 6-bromo-4-(3-chlorophenyl)-2-methoxy-quinoline
|
CN100567292C
(zh)
|
2004-05-03 |
2009-12-09 |
詹森药业有限公司 |
制备咪唑化合物的非对映选择性合成方法
|
US7524961B2
(en)
|
2004-05-03 |
2009-04-28 |
Janssen Pharmaceutica, N.V. |
Diastereoselective addition of lithiated N-methylimidazole on sulfinimines
|
EP1765313A2
(en)
|
2004-06-24 |
2007-03-28 |
Novartis Vaccines and Diagnostics, Inc. |
Compounds for immunopotentiation
|
GB0420722D0
(en)
|
2004-09-17 |
2004-10-20 |
Addex Pharmaceuticals Sa |
Novel allosteric modulators
|
CA2585717A1
(en)
|
2004-10-27 |
2006-05-04 |
Medimmune Inc. |
Modulation of antibody specificity by tailoring the affinity to cognate antigens
|
PT1815247E
(pt)
|
2004-11-05 |
2013-04-23 |
Janssen Pharmaceutica Nv |
Uso terapêutico de inibidores de farnesiltransferase e métodos para monitorizar a eficácia do mesmo
|
US20060194821A1
(en)
*
|
2005-02-18 |
2006-08-31 |
The Brigham And Women's Hospital, Inc. |
Compounds inhibiting the aggregation of superoxide dismutase-1
|
AU2006227377B2
(en)
|
2005-03-18 |
2013-01-31 |
Medimmune, Llc |
Framework-shuffling of antibodies
|
WO2006123182A2
(en)
|
2005-05-17 |
2006-11-23 |
Merck Sharp & Dohme Limited |
Cyclohexyl sulphones for treatment of cancer
|
US20060281769A1
(en)
*
|
2005-06-10 |
2006-12-14 |
Baumann Christian A |
Synergistic modulation of flt3 kinase using thienopyrimidine and thienopyridine kinase modulators
|
US20070004660A1
(en)
*
|
2005-06-10 |
2007-01-04 |
Baumann Christian A |
Synergistic Modulation of Flt3 Kinase Using Alkylquinolines and Alkylquinazolines
|
US20060281755A1
(en)
*
|
2005-06-10 |
2006-12-14 |
Baumann Christian A |
Synergistic modulation of flt3 kinase using aminopyrimidines kinase modulators
|
US20060281788A1
(en)
*
|
2005-06-10 |
2006-12-14 |
Baumann Christian A |
Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
|
KR20080025174A
(ko)
|
2005-06-23 |
2008-03-19 |
메디뮨 인코포레이티드 |
응집 및 단편화 프로파일이 최적화된 항체 제제
|
JP5225092B2
(ja)
*
|
2005-10-14 |
2013-07-03 |
ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ |
チピファルニブの新規iv調合物
|
WO2007075923A2
(en)
|
2005-12-23 |
2007-07-05 |
Link Medicine Corporation |
Treatment of synucleinopathies
|
JO2660B1
(en)
|
2006-01-20 |
2012-06-17 |
نوفارتيس ايه جي |
Pi-3 inhibitors and methods of use
|
GB0603041D0
(en)
|
2006-02-15 |
2006-03-29 |
Angeletti P Ist Richerche Bio |
Therapeutic compounds
|
TWI417095B
(zh)
|
2006-03-15 |
2013-12-01 |
Janssen Pharmaceuticals Inc |
1,4-二取代之3-氰基-吡啶酮衍生物及其作為mGluR2-受體之正向異位性調節劑之用途
|
AR060358A1
(es)
|
2006-04-06 |
2008-06-11 |
Novartis Vaccines & Diagnostic |
Quinazolinas para la inhibicion de pdk 1
|
AU2007240437B2
(en)
|
2006-04-20 |
2012-12-06 |
Janssen Pharmaceutica N.V. |
Heterocyclic compounds as inhibitors of c-fms kinase
|
BRPI0710548B8
(pt)
|
2006-04-20 |
2021-05-25 |
Janssen Pharmaceutica Nv |
inibidores de c-fms cinase, composição farmacêutica e forma de dosagem farmacêutica
|
US8697716B2
(en)
|
2006-04-20 |
2014-04-15 |
Janssen Pharmaceutica Nv |
Method of inhibiting C-KIT kinase
|
MX2009002151A
(es)
|
2006-08-28 |
2009-07-03 |
Kirin Pharma Kk |
Anticuerpos monoclonales humanos especificos para light humano antagonistas.
|
EP2083831B1
(en)
|
2006-09-22 |
2013-12-25 |
Merck Sharp & Dohme Corp. |
Method of treatment using fatty acid synthesis inhibitors
|
US20110218176A1
(en)
|
2006-11-01 |
2011-09-08 |
Barbara Brooke Jennings-Spring |
Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
|
EP2336120B1
(en)
|
2007-01-10 |
2014-07-16 |
MSD Italia S.r.l. |
Combinations containing amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors
|
JP5330274B2
(ja)
|
2007-03-01 |
2013-10-30 |
ノバルティス アーゲー |
Pimキナーゼ阻害剤およびその使用方法
|
TW200900065A
(en)
|
2007-03-07 |
2009-01-01 |
Janssen Pharmaceutica Nv |
3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
|
TW200845978A
(en)
|
2007-03-07 |
2008-12-01 |
Janssen Pharmaceutica Nv |
3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
|
EP2077859A4
(en)
|
2007-03-30 |
2010-11-24 |
Medimmune Llc |
ANTIBODY FORMULATION
|
JO2959B1
(en)
|
2007-05-14 |
2016-03-15 |
جانسين فارماسوتيكا ان. في |
Mono-hydrochloric salts for histone dacetylase inhibitor
|
AU2008254425A1
(en)
|
2007-05-21 |
2008-11-27 |
Novartis Ag |
CSF-1R inhibitors, compositions, and methods of use
|
DK2160386T3
(da)
*
|
2007-05-23 |
2012-08-27 |
Allergan Inc |
Terapeutiske ((phenyl)imidazolyl)methylquinolinylforbindelser
|
US8389553B2
(en)
|
2007-06-27 |
2013-03-05 |
Merck Sharp & Dohme Corp. |
4-carboxybenzylamino derivatives as histone deacetylase inhibitors
|
EA019085B1
(ru)
|
2007-09-14 |
2014-01-30 |
Янссен Фармасьютикалз, Инк. |
1',3-двузамещенные 4-(арил-х-фенил)-1н-пиридин-2-оны
|
US9114138B2
(en)
|
2007-09-14 |
2015-08-25 |
Janssen Pharmaceuticals, Inc. |
1′,3′-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2H,1′H-[1,4′] bipyridinyl-2′-ones
|
JO3240B1
(ar)
|
2007-10-17 |
2018-03-08 |
Janssen Pharmaceutica Nv |
c-fms مثبطات كيناز
|
BRPI0818810A2
(pt)
|
2007-10-31 |
2014-10-29 |
Medimmune Llc |
Esqueletos d polipeptídeo recombinante e multimérico, molécula de ácido n ucleico isolado, vetor de expressão, célula hospedeira, biblioteca de exibição de polipeptídeo, coleção de moléculas de ácido nucleico isolado, métodos para obter um esqueleto de polipeptídeo e pelo menos dois esqueletos, para detectar um composto em uma amostra, para capturar um composto em uma amostra, para prevenir, tratar, controlar ou melhorar uma doença, para diagnose ou formação de imagem de uma doença para purificar e produzir um esqueleto, para ensaiar ou detectar a ligação de um esqueleto a um alvo, para usar o esqueleto e para prevenir, tratar, melhora ou controlar câncer, composição estéril, isenta de pirógeno, composição farmacêutica, e, processo escalável.
|
CA2708281A1
(en)
|
2007-12-11 |
2009-08-27 |
Viamet Pharmaceuticals, Inc. |
Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties
|
PA8809001A1
(es)
|
2007-12-20 |
2009-07-23 |
Novartis Ag |
Compuestos organicos
|
US7932036B1
(en)
|
2008-03-12 |
2011-04-26 |
Veridex, Llc |
Methods of determining acute myeloid leukemia response to treatment with farnesyltransferase
|
US8232402B2
(en)
*
|
2008-03-12 |
2012-07-31 |
Link Medicine Corporation |
Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications
|
WO2010025890A1
(en)
|
2008-09-02 |
2010-03-11 |
Ortho-Mcneil-Janssen Pharmaceuticals, Inc |
3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
|
BRPI0921113A2
(pt)
*
|
2008-11-13 |
2016-02-16 |
Link Medicine Corp |
tratamento de proteinopatias usando um inibidor de farnesil transferase.
|
JP2012508768A
(ja)
*
|
2008-11-13 |
2012-04-12 |
リンク・メディスン・コーポレーション |
アザキノリノン誘導体及びその使用
|
US20100331363A1
(en)
*
|
2008-11-13 |
2010-12-30 |
Link Medicine Corporation |
Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
|
US20110060005A1
(en)
*
|
2008-11-13 |
2011-03-10 |
Link Medicine Corporation |
Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
|
AU2009319387B2
(en)
|
2008-11-28 |
2012-05-10 |
Addex Pharma S.A. |
Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
|
US8691825B2
(en)
|
2009-04-01 |
2014-04-08 |
Merck Sharp & Dohme Corp. |
Inhibitors of AKT activity
|
CA2760259C
(en)
|
2009-05-12 |
2018-05-01 |
Janssen Pharmaceuticals, Inc. |
1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
|
MY153913A
(en)
|
2009-05-12 |
2015-04-15 |
Janssen Pharmaceuticals Inc |
7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
|
JP5634506B2
(ja)
|
2009-05-12 |
2014-12-03 |
ジャンセン ファーマシューティカルズ, インコーポレイテッド |
1,2,3−トリアゾロ[4,3−a]ピリジン誘導体ならびに神経障害および精神障害の治療または予防のためのその使用
|
US8765747B2
(en)
|
2009-06-12 |
2014-07-01 |
Dana-Farber Cancer Institute, Inc. |
Fused 2-aminothiazole compounds
|
US8293753B2
(en)
|
2009-07-02 |
2012-10-23 |
Novartis Ag |
Substituted 2-carboxamide cycloamino ureas
|
KR101485645B1
(ko)
|
2009-10-14 |
2015-01-22 |
머크 샤프 앤드 돔 코포레이션 |
p53 활성을 증가시키는 치환된 피페리딘 및 그의 용도
|
US9180127B2
(en)
|
2009-12-29 |
2015-11-10 |
Dana-Farber Cancer Institute, Inc. |
Type II Raf kinase inhibitors
|
KR20130006664A
(ko)
|
2010-03-16 |
2013-01-17 |
다나-파버 캔서 인스티튜트 인크. |
인다졸 화합물 및 그의 용도
|
US8999957B2
(en)
|
2010-06-24 |
2015-04-07 |
Merck Sharp & Dohme Corp. |
Heterocyclic compounds as ERK inhibitors
|
CN103328971B
(zh)
|
2010-07-28 |
2016-09-28 |
维里德克斯有限责任公司 |
急性髓细胞性白血病应答法尼基转移酶抑制剂治疗的测定方法
|
AR082418A1
(es)
|
2010-08-02 |
2012-12-05 |
Novartis Ag |
Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico
|
CN107090456B
(zh)
|
2010-08-02 |
2022-01-18 |
瑟纳治疗公司 |
使用短干扰核酸的RNA干扰介导的联蛋白(钙粘蛋白关联蛋白质),β1基因表达的抑制
|
EP4079856A1
(en)
|
2010-08-17 |
2022-10-26 |
Sirna Therapeutics, Inc. |
Rna interference mediated inhibition of hepatitis b virus (hbv) gene expression using short interfering nucleic acid (sina)
|
EP2608669B1
(en)
|
2010-08-23 |
2016-06-22 |
Merck Sharp & Dohme Corp. |
NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
|
WO2012030685A2
(en)
|
2010-09-01 |
2012-03-08 |
Schering Corporation |
Indazole derivatives useful as erk inhibitors
|
EP2615916B1
(en)
|
2010-09-16 |
2017-01-04 |
Merck Sharp & Dohme Corp. |
Fused pyrazole derivatives as novel erk inhibitors
|
WO2012058210A1
(en)
|
2010-10-29 |
2012-05-03 |
Merck Sharp & Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
|
JP5852666B2
(ja)
|
2010-11-08 |
2016-02-03 |
ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド |
1,2,4−トリアゾロ[4,3−a]ピリジン誘導体およびmGluR2受容体のポジティブアロステリックモジュレーターとしてのそれらの使用
|
JP5852665B2
(ja)
|
2010-11-08 |
2016-02-03 |
ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド |
1,2,4−トリアゾロ[4,3−a]ピリジン誘導体およびmGluR2受容体のポジティブアロステリックモジュレーターとしてのそれらの使用
|
ES2552455T3
(es)
|
2010-11-08 |
2015-11-30 |
Janssen Pharmaceuticals, Inc. |
Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2
|
EP2654748B1
(en)
|
2010-12-21 |
2016-07-27 |
Merck Sharp & Dohme Corp. |
Indazole derivatives useful as erk inhibitors
|
WO2012103165A2
(en)
|
2011-01-26 |
2012-08-02 |
Kolltan Pharmaceuticals, Inc. |
Anti-kit antibodies and uses thereof
|
PE20140293A1
(es)
|
2011-01-31 |
2014-03-19 |
Novartis Ag |
Novedosos derivados heterociclicos
|
US20140045847A1
(en)
|
2011-04-21 |
2014-02-13 |
Piramal Enterprises Limited |
Crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
|
EP2770987B1
(en)
|
2011-10-27 |
2018-04-04 |
Merck Sharp & Dohme Corp. |
Novel compounds that are erk inhibitors
|
EP2771342B1
(en)
|
2011-10-28 |
2016-05-18 |
Novartis AG |
Purine derivatives and their use in the treatment of disease
|
WO2013074986A1
(en)
|
2011-11-17 |
2013-05-23 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of c-jun-n-terminal kinase (jnk)
|
EP2844261B1
(en)
|
2012-05-02 |
2018-10-17 |
Sirna Therapeutics, Inc. |
SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
|
AU2013263043B2
(en)
|
2012-05-16 |
2016-06-16 |
Novartis Ag |
Dosage regimen for a PI-3 kinase inhibitor
|
NZ630363A
(en)
|
2012-07-25 |
2018-09-28 |
Celldex Therapeutics Inc |
Anti-kit antibodies and uses thereof
|
JOP20180012A1
(ar)
|
2012-08-07 |
2019-01-30 |
Janssen Pharmaceutica Nv |
عملية السلفنة باستخدام نونافلوروبوتانيسولفونيل فلوريد
|
EP2882757B1
(en)
|
2012-08-07 |
2016-10-05 |
Janssen Pharmaceutica, N.V. |
Process for the preparation of heterocyclic ester derivatives
|
EP2900241B1
(en)
|
2012-09-28 |
2018-08-08 |
Merck Sharp & Dohme Corp. |
Novel compounds that are erk inhibitors
|
SG11201502757QA
(en)
|
2012-10-09 |
2015-05-28 |
Igenica Biotherapeutics Inc |
Anti-c16orf54 antibodies and methods of use thereof
|
PL2909192T3
(pl)
|
2012-10-16 |
2017-09-29 |
Janssen Pharmaceutica Nv |
Połączone metylenem modulatory chinolinylowe ROR-GAMMA-T
|
CN105073729A
(zh)
|
2012-10-16 |
2015-11-18 |
詹森药业有限公司 |
RORγt的苯基连接的喹啉基调节剂
|
KR20150070348A
(ko)
|
2012-10-16 |
2015-06-24 |
얀센 파마슈티카 엔.브이. |
RoRγt의 헤테로아릴 결합 퀴놀리닐 조절제
|
EP2909194A1
(en)
|
2012-10-18 |
2015-08-26 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinase 7 (cdk7)
|
US9758522B2
(en)
|
2012-10-19 |
2017-09-12 |
Dana-Farber Cancer Institute, Inc. |
Hydrophobically tagged small molecules as inducers of protein degradation
|
WO2014063054A1
(en)
|
2012-10-19 |
2014-04-24 |
Dana-Farber Cancer Institute, Inc. |
Bone marrow on x chromosome kinase (bmx) inhibitors and uses thereof
|
SI2925888T1
(en)
|
2012-11-28 |
2018-02-28 |
Merck Sharp & Dohme Corp. |
Compounds and methods for the treatment of cancer
|
RU2690663C2
(ru)
|
2012-12-20 |
2019-06-05 |
Мерк Шарп И Доум Корп. |
Замещенные имидазопиридины в качестве ингибиторов hdm2
|
US9540377B2
(en)
|
2013-01-30 |
2017-01-10 |
Merck Sharp & Dohme Corp. |
2,6,7,8 substituted purines as HDM2 inhibitors
|
JO3368B1
(ar)
|
2013-06-04 |
2019-03-13 |
Janssen Pharmaceutica Nv |
مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
|
US10100123B2
(en)
|
2013-06-06 |
2018-10-16 |
Pierre Fabre Medicament |
Anti-C10orf54 antibodies and uses thereof
|
KR20160054501A
(ko)
|
2013-08-26 |
2016-05-16 |
맵백스 테라퓨틱스, 인코포레이티드 |
시알릴-루이스 a에 대한 사람 항체 코드화 핵산
|
EP3041938A1
(en)
|
2013-09-03 |
2016-07-13 |
Moderna Therapeutics, Inc. |
Circular polynucleotides
|
JO3367B1
(ar)
|
2013-09-06 |
2019-03-13 |
Janssen Pharmaceutica Nv |
مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
|
WO2015057626A1
(en)
|
2013-10-15 |
2015-04-23 |
Janssen Pharmaceutica Nv |
QUINOLINYL MODULATORS OF RORyT
|
US9284308B2
(en)
|
2013-10-15 |
2016-03-15 |
Janssen Pharmaceutica Nv |
Methylene linked quinolinyl modulators of RORγt
|
US9403816B2
(en)
|
2013-10-15 |
2016-08-02 |
Janssen Pharmaceutica Nv |
Phenyl linked quinolinyl modulators of RORγt
|
US9221804B2
(en)
|
2013-10-15 |
2015-12-29 |
Janssen Pharmaceutica Nv |
Secondary alcohol quinolinyl modulators of RORγt
|
US9328095B2
(en)
|
2013-10-15 |
2016-05-03 |
Janssen Pharmaceutica Nv |
Heteroaryl linked quinolinyl modulators of RORgammat
|
WO2015057629A1
(en)
|
2013-10-15 |
2015-04-23 |
Janssen Pharmaceutica Nv |
ALKYL LINKED QUINOLINYL MODULATORS OF RORyt
|
US10555941B2
(en)
|
2013-10-15 |
2020-02-11 |
Janssen Pharmaceutica Nv |
Alkyl linked quinolinyl modulators of RORγt
|
AU2014337044A1
(en)
|
2013-10-18 |
2016-05-05 |
Dana-Farber Cancer Institute, Inc. |
Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7)
|
CA2927917C
(en)
|
2013-10-18 |
2022-08-09 |
Syros Pharmaceuticals, Inc. |
Heteroaromatic compounds useful for the treatment of proliferative diseases
|
TN2016000179A1
(en)
|
2013-12-06 |
2017-10-06 |
Novartis Ag |
Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor.
|
LT3096790T
(lt)
|
2014-01-21 |
2019-10-10 |
Janssen Pharmaceutica, N.V. |
Deriniai, apimantys 2 potipio metabotropinio glutamaterginio receptoriaus teigiamus alosterinius moduliatorius arba ortosterinius agonistus, ir jų panaudojimas
|
WO2015110435A1
(en)
|
2014-01-21 |
2015-07-30 |
Janssen Pharmaceutica Nv |
Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
WO2015164614A1
(en)
|
2014-04-23 |
2015-10-29 |
Dana-Farber Cancer Institute, Inc. |
Janus kinase inhibitors and uses thereof
|
WO2015164604A1
(en)
|
2014-04-23 |
2015-10-29 |
Dana-Farber Cancer Institute, Inc. |
Hydrophobically tagged janus kinase inhibitors and uses thereof
|
US11311519B2
(en)
|
2014-05-01 |
2022-04-26 |
Eiger Biopharmaceuticals, Inc. |
Treatment of hepatitis delta virus infection
|
US10076512B2
(en)
|
2014-05-01 |
2018-09-18 |
Eiger Biopharmaceuticals, Inc. |
Treatment of hepatitis delta virus infection
|
WO2015187811A2
(en)
|
2014-06-04 |
2015-12-10 |
MabVax Therapeutics, Inc. |
Human monoclonal antibodies to ganglioside gd2
|
JO3589B1
(ar)
|
2014-08-06 |
2020-07-05 |
Novartis Ag |
مثبطات كيناز البروتين c وطرق استخداماتها
|
ES2834739T3
(es)
|
2014-12-11 |
2021-06-18 |
Pf Medicament |
Anticuerpos anti-C10orf54 y utilizaciones de los mismos
|
CA2972239A1
(en)
|
2014-12-23 |
2016-06-30 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinase 7 (cdk7)
|
PL3265123T3
(pl)
|
2015-03-03 |
2023-03-13 |
Kymab Limited |
Przeciwciała, zastosowania i sposoby
|
EP3273966B1
(en)
|
2015-03-27 |
2023-05-03 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinases
|
EP3285768B1
(en)
|
2015-04-21 |
2020-12-30 |
Eiger Biopharmaceuticals, Inc. |
Pharmaceutical compositions comprising lonafarnib and ritonavir
|
AU2016276963C1
(en)
|
2015-06-12 |
2021-08-05 |
Dana-Farber Cancer Institute, Inc. |
Combination therapy of transcription inhibitors and kinase inhibitors
|
DK3277842T5
(da)
|
2015-08-17 |
2020-08-31 |
Kura Oncology Inc |
Fremgangsmåder til at behandle kræftpatienter med farnesyl-transferase-inhibitorer
|
WO2017034877A1
(en)
*
|
2015-08-27 |
2017-03-02 |
Janssen Pharmaceutica Nv |
Chemically modified quinoline and quinolone derivatives useful as cb-1 inverse agonists
|
WO2017044858A2
(en)
|
2015-09-09 |
2017-03-16 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinases
|
RU2018119085A
(ru)
|
2015-11-02 |
2019-12-04 |
Новартис Аг |
Схема введения ингибитора фосфатидилинозитол-3-киназы
|
CN108925136B
(zh)
|
2015-12-02 |
2022-02-01 |
斯特赛恩斯公司 |
特异于糖基化的btla(b和t淋巴细胞衰减因子)的抗体
|
CN114470194A
(zh)
|
2015-12-02 |
2022-05-13 |
斯特库伯株式会社 |
与btn1a1免疫特异性结合的抗体和分子及其治疗用途
|
JOP20190055A1
(ar)
|
2016-09-26 |
2019-03-24 |
Merck Sharp & Dohme |
أجسام مضادة ضد cd27
|
WO2018060833A1
(en)
|
2016-09-27 |
2018-04-05 |
Novartis Ag |
Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib
|
EP3534947A1
(en)
|
2016-11-03 |
2019-09-11 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses & methods
|
KR20190082247A
(ko)
|
2016-11-03 |
2019-07-09 |
쿠라 온콜로지, 인크. |
파르네실전달효소 억제제를 이용하여 암 환자를 치료하는 방법
|
US10954210B2
(en)
|
2016-12-08 |
2021-03-23 |
Hangzhou Solipharma Co., Ltd. |
Crystal form of tipifarnib and preparation method and pharmaceutical composition thereof
|
CN118267470A
(zh)
|
2017-04-13 |
2024-07-02 |
赛罗帕私人有限公司 |
抗SIRPα抗体
|
US20200131266A1
(en)
|
2017-05-31 |
2020-04-30 |
Stcube & Co., Inc. |
Methods of treating cancer using antibodies and molecules that immunospecifically bind to btn1a1
|
AU2018277838A1
(en)
|
2017-05-31 |
2019-12-19 |
Stcube & Co., Inc. |
Antibodies and molecules that immunospecifically bind to BTN1A1 and the therapeutic uses thereof
|
JP2020522562A
(ja)
|
2017-06-06 |
2020-07-30 |
ストキューブ アンド シーオー., インコーポレイテッド |
Btn1a1又はbtn1a1リガンドに結合する抗体及び分子を用いて癌を治療する方法
|
WO2019073069A1
(en)
|
2017-10-13 |
2019-04-18 |
Boehringer Ingelheim International Gmbh |
HUMAN ANTIBODIES AGAINST THOMSEN-NEW ANTIGEN (TN)
|
US10947234B2
(en)
|
2017-11-08 |
2021-03-16 |
Merck Sharp & Dohme Corp. |
PRMT5 inhibitors
|
WO2019113269A1
(en)
|
2017-12-08 |
2019-06-13 |
Kura Oncology, Inc. |
Methods of treating cancer patients with farnesyltransferase inhibitors
|
WO2019148412A1
(en)
|
2018-02-01 |
2019-08-08 |
Merck Sharp & Dohme Corp. |
Anti-pd-1/lag3 bispecific antibodies
|
AU2019270163A1
(en)
|
2018-05-18 |
2020-12-03 |
Kura Oncology, Inc. |
Synthesis of tipifarnib
|
MX2021000786A
(es)
|
2018-07-20 |
2021-06-15 |
Pf Medicament |
Receptor para supresor de ig del dominio v de activación de células t (vista).
|
US11981701B2
(en)
|
2018-08-07 |
2024-05-14 |
Merck Sharp & Dohme Llc |
PRMT5 inhibitors
|
EP3833668A4
(en)
|
2018-08-07 |
2022-05-11 |
Merck Sharp & Dohme Corp. |
PRMT5 INHIBITORS
|
TW202108170A
(zh)
|
2019-03-15 |
2021-03-01 |
美商庫拉腫瘤技術股份有限公司 |
以法呢基轉移酶(farnesyltransferase)抑制劑治療癌症患者之方法
|
TW202327590A
(zh)
|
2021-11-30 |
2023-07-16 |
美商庫拉腫瘤技術股份有限公司 |
大環化合物及組合物以及其製備及使用方法
|
WO2023141082A1
(en)
*
|
2022-01-20 |
2023-07-27 |
Teva Czech Industries S.R.O. |
Solid state forms of tipifarnib and process for preparation thereof
|